Introduction {#s1}
============

Neurodevelopmental disorders (NDDs), including intellectual disability (ID), autism spectrum disorder (ASD), and epilepsy result in treatment-resistant behavioral abnormalities. Many severe NDDs are characterized by cognitive impairments and medically-refractory seizures ([@bib4]; [@bib24]). In some cases, seizures, and underlying circuit-level excitatory imbalances that trigger these events, are thought to contribute to worsening of cognitive and behavioral phenotypes ([@bib46]). Therefore, it is crucial to develop treatment strategies that improve the function of neural circuits associated with seizure susceptibility and cognitive impairment in NDD patient populations.

Historically, the patho-neurobiology underlying NDD symptomatology is thought to arise from impaired brain development. However, studies in animal models of genetic risk factors causally-linked to syndromic NDDs have shown improvement in meaningful measures of brain function and behavior in response to adult-initiated therapeutic interventions ([@bib19]; [@bib13]; [@bib9]). These findings suggest that not all phenotypic consequences of NDDs arise through impaired neurodevelopment indicating that therapeutic intervention may be beneficial in adult NDD patients with fully mature brains ([@bib54]; [@bib14]). The potential impact of adult initiated treatments in NDD patients cannot be overstated, as there are currently no effective treatments for the most debilitating aspects of these disorders. Thus, hope remains that adults with NDDs could benefit from emerging therapeutic strategies.

Adult reversal studies have been carried out in animal models for only a few syndromic NDD genes ([@bib14]). In these models, with some notable exceptions, phenotypic reversal in adulthood is most effective in correcting social behaviors and/or motor function ([@bib19]; [@bib14]; [@bib31]; [@bib32]). However, there is less evidence that adult-initiated treatments can improve both cognitive dysfunction and seizure susceptibility in animal models for human disorders that are defined by these core phenotypes. Over the past decade, hundreds of new genes have been linked to NDDs ([@bib51]). Large-scale exome sequencing projects in children with classically undefined and sporadic NDDs have identified a pool of genes that infer 100% (i.e. causal) risk for developing a severe disorder caused by brain dysfunction ([@bib10]; [@bib11]; [@bib29]). Some of these newer NDD genes account for a significant fraction of total cases, and dramatic phenotypes, such as severe cognitive impairment and medically-refractory seizures, define these single gene disorders ([@bib10]; [@bib11]). Given that the list of completely penetrant NDD genes has expanded considerably over the last decade, it is critical to understand the effectiveness of adult-initiated treatments in animal models for these newly-discovered single gene disorders. Moreover, it is important to gauge to what extent emerging treatment strategies improve cognitive impairment and seizure susceptibility because these are two of the most debilitating outcomes associated with the most severe genetically-defined NDDs.

*SYNGAP1* is a recently discovered NDD gene ([@bib22]; [@bib53]; [@bib20]), causally-linked to a range of sporadic disorders, including ID ([@bib10]; [@bib11]; [@bib20]; [@bib45]), ASD ([@bib29]; [@bib38]; [@bib21]), severe epilepsy ([@bib49]; [@bib5]; [@bib50]) and schizophrenia ([@bib44]). De novo nonsense variants in *SYNGAP1* resulting in haploinsufficiency lead to a relatively frequent genetically-defined form of ID with epilepsy (termed MRD5; OMIM\#603384). It has a reported incidence of 1-4/10,000 individuals, or 0.5--1.0% of ID cases ([@bib10]; [@bib11]; [@bib29]; [@bib3]; [@bib41]), which is similar to the frequency of Fragile X syndrome. MRD5 patients express moderate-to-severe intellectual disability (IQ \< 50), have severely delayed language development, and express some form of epilepsy and/or abnormal brain activity, with these manifestations appearing first in early childhood ([@bib49]; [@bib3]; [@bib41]; [@bib34]). *SYNGAP1* has been recognized as a high-priority risk gene worthy of in-depth study. This designation was first suggested based on its causal linkage to a broad range of neuropsychiatric disorders ([@bib22]; [@bib53]). This notion is strengthened by the known biological functions of SynGAP protein. A major function of the protein is to integrate signaling through NMDA receptors with structural and functional synapse plasticity ([@bib26]), which is a substrate shared among nearly all neuropsychiatric disorders ([@bib43]). Therefore, biological discoveries made in *Syngap1* mouse models may be broadly generalizable to idiopathic neuropsychiatric disorders.

*Syngap1* heterozygous knockout mice (Hets), which have \~50% reduction in SynGAP protein levels ([@bib6]), offer both construct and face validity for MRD5 ([@bib26]). *Syngap1* heterozygosity disrupts a developmental critical period, in which a normal ratio of excitatory and inhibitory synapses are formed in particular brain regions. Without this normal ratio, circuits can become overly excitable, which may contribute to pathological brain function ([@bib6]; [@bib1]; [@bib7]; [@bib39]). Prior studies have shown that reduced *Syngap1* expression during this developmental critical period prevents the normal emergence of certain behavioral responses and cognitive functions because altered measures of working memory, locomotor activity, and anxiety are sensitive to neonatal reversal of *Syngap1* pathogenicity ([@bib1]) but resistant to similar approaches performed in adulthood ([@bib6]). However, knocking out SynGAP protein in the adult hippocampus causes memory impairments ([@bib37]) and increases seizure susceptibility ([@bib39]), suggesting that *Syngap1* may also have unique, non-developmental functions in the adult brain that promotes cognitive function and suppresses neural excitability. *Syngap1* mice have an extensive endophenotype ([@bib6]; [@bib39]; [@bib18]; [@bib36]). However, only a small subset of individual phenotypes have been tested for sensitivity to adult reversal of genetic pathogenicity in this line of mice ([@bib6]). Based on these past results, we determined if robust disease-associated phenotypes in *Syngap1* mice, such as long-term memory and seizure susceptibility, are sensitive to a method of adult gene restoration that boosts pathologically low levels of SynGAP protein. Moreover, we also searched for neurophysiological correlates of behavioral alterations in *Syngap1* animals to gain insight into how protein re-expression in mature animals may improve brain function related to cognitive ability and seizure.

Results {#s2}
=======

Epileptic encephalopathy (EE) is one outcome of pathogenic *SYNGAP1* variation ([@bib5]). EE is a childhood neurological condition where epileptiform activity is believed to cause progressive worsening of brain function. Consistent with an EE designation, a substantial portion of MRD5 patients exhibit regressive phenotypes and are medically refractory to anti-epileptic drugs ([@bib49]). *Syngap1* mice also express electrographic and behavioral seizures ([@bib34]; [@bib39]; [@bib52]). Therefore, these animals can be used as a model for understanding how seizure-related phenotypes associated with MRD5 are modified by adult-initiated therapies. To do this, we used a *Syngap1* heterozygous (Het) animal model that enables whole-body SynGAP protein re-expression at different stages of life ([@bib6]; [@bib39]). This model is created by crossing *Syngap1* Lox-stop Het mice (*Syngap1^+/ls^)* to hemizygous mice expressing a tamoxifen (TMX)-inducible form of Cre recombinase. Upon Cre activation, an artificial exon containing a premature stop codon is excised from the *Syngap1* gene, leading to re-activation of the targeted allele and restoration of SynGAP protein levels. To test for seizure susceptibility, we used the flurothyl seizure induction paradigm, which has been used previously to uncover phenotypes in constitutive *Syngap1* Het knockout mice ([@bib6]). In this paradigm, flurothyl exposure leads to gradually progressing seizure types, and seizure susceptibility is quantified by recording the latency to reach each distinct seizure stage. In TMX(-) mice, there was a main effect of *Syngap1* genotype (i.e. the presence of the Lox-Stop allele), but not with the presence of Cre-ER, in the first two stages of seizure ([Figure 1A](#fig1){ref-type="fig"}; [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). There was no interaction detected between these two factors during any of the stages. The pairwise comparisons indicated that both Cre(-) and Cre(+) *Syngap1* Lox-Stop Hets reached the first two stages of seizure significantly faster than the corresponding *Syngap1* WT mice ([Figure 1A](#fig1){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}), which is indicative of a reduced seizure threshold and replicates our previous findings in adult constitutive *Syngap1* Het knockout mice ([@bib39]). Importantly, there was no statistical difference between Cre(-) and Cre(+) *Syngap1* Lox-Stop Hets, indicating that Cre remained largely inactive in Cre(+)TMX(-) mice ([Figure 1A](#fig1){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}).

![Seizure threshold is improved after adult restoration of SynGAP expression.\
(**A**) *Syngap^Cre-;+/ls^* and *Syngap^Cre+;+/ls^* mice exhibit hyperexcitability in two of the three events without Cre activation (No TMX) Main effects-1^st^ clonus: Cre F(1,24)=2.13, p=0.157, Genotype F = 117.73, p=9.75E-11, Interaction F(1,24)=1.69, p=0.206); Cre- Cohen's d = 3.855, Cre +Cohen's d = 4.737. TC: Cre F(1,24)=722, p=0.404, Genotype F(1,24)=40.05, p=1.53E-6), Interaction F(1,24)=.257, p=0.617); Cre- Cohen's d = 2.396, Cre+ Cohen's d = 2.405. THE: Cre F(1,24)=9.99E-6, p=0.998, Genotype F(1,24)=.320, p=0.577), Interaction F(1,24)=.420, p=0.523. (**B**) *Syngap^Cre+;+/ls^* mice exhibit thresholds comparable to those of *Syngap^Cre-;+/ls^* mice after Cre activation (TMX-treated) in two of the three events Main effects-1^st^ clonus: Cre F(1,71)=2.59, p=0.112; Genotype F(1,71)=58.328, p=7.86E-11, Interaction F = 1 (1,71)=18.84 p=4.62E-5; Cre- Cohen's d = 3.329, Cre+ Cohen's d = 0.674; TC: Cre F(1,71)=4.53, p=0.037, Genotype F(1,71)=26.15, p=2.57E-6, Interaction F(1,71)=6.50, p=0.013; Cre- Cohen's d = 2.040; Cre+ Cohen\'s d = 0.540; THE: Cre F(1,71)=.037, p=0.847, Genotype F(1,71)=1.15E-5, p=0.997, Interaction F(1,71)=.049, p=0.826. Data points (and numbers) in bars represent biological replicates (animals). Data from panel B are pooled from two separate experiments.\
10.7554/eLife.46752.005Figure 1---source data 1.Source data for [Figure 1A](#fig1){ref-type="fig"}.\
10.7554/eLife.46752.006Figure 1---source data 2.Source data for [Figure 1B](#fig1){ref-type="fig"}.](elife-46752-fig1){#fig1}

In TMX-treated mice, for the first two seizure stages, there was again an effect of the Lox-Stop allele, but not for Cre-ER ([Figure 1B](#fig1){ref-type="fig"}). However, we detected an interaction between Lox-Stop and Cre-ER in this study ([Figure 1B](#fig1){ref-type="fig"}). This suggested that restoration of SynGAP protein in adulthood influenced seizure threshold measurements. Pairwise comparisons of all four genotypes demonstrated that TMX improved the seizure threshold in Cre(+) Lox-Stop mice. For example, Cre(+) *Syngap1* Lox-Stop Het mice, or mice with *Syngap1* pathogenicity reversed starting at PND60 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [Supplementary file 2](#supp2){ref-type="supplementary-material"}; [Figure 1---figure supplement 1---source data 1](#fig1s1sdata1){ref-type="supplementary-material"}), were not statistically different from Cre(+) WT *Syngap1* mice in the second seizure stage ([Figure 1B](#fig1){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}; [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). This demonstrates that TMX increased the latency to tonic-clonic seizure induction in Lox-Stop mice to WT levels. Consistent with this, the same comparison during the first seizure stage uncovered a large difference in effect size between Cre(+) WT and Cre(+) Lox-Stop mice. Furthermore, the latency to seizure induction in Cre(+) *Syngap1* Lox-Stop mice was significantly increased compared to Cre(-) *Syngap1* Hets in the first two stages of the test ([Figure 1B](#fig1){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}; [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). Together, these data demonstrate that SynGAP re-expression in adulthood improves seizure threshold in *Syngap1* haploinsufficient mice.

Given the behavioral improvements in response to SynGAP re-expression in adult Cre(+)/Lox-Stop Het mice, we explored how this approach impacts neurophysiological correlates of seizure susceptibility. Prior studies have shown through EEG recordings that constitutive *Syngap1* heterozygous knockout mice display frequent high-amplitude interictal spiking (IIS) events in addition to occasional electrographic seizure events ([@bib39]). Interictal spikes (IIS) are pathological electrical events that reflect seizure susceptibility in patients and may share common mechanisms with ictal events ([@bib25]). We reasoned that because behavioral seizure susceptibility was reversed after SynGAP re-expression in Cre(+)/Lox-Stop Hets, IIS events may also be ameliorated by this therapeutic approach. However, neurophysiological studies have not been performed in *Syngap1* Lox-Stop mice. Therefore, it is unknown if IIS events are present in this line. We performed in vivo neurophysiological recordings in both Cre(+) WT and Cre(+) Lox-Stop Het mice. In addition to left and right sub-cranial EEG electrodes, a depth electrode was lowered into CA1 to acquire a hippocampal local field potential (*h*LFP). A study utilizing chronic recordings in these animals consisted of two phases. Phase one was geared toward identifying putative genotype-dependent differences in neurophysiological signals between Cre(+) WT and Cre(+) Lox-Stop mice. Phase II, in which all animals in Phase I underwent a procedure to induce Cre recombinase immediately following Phase I studies, was geared toward determining how putative neurophysiological abnormalities in each animal were impacted by restoration of SynGAP levels in Cre(+) Lox-Stop Het mice. In Phase I recordings, we observed frequent high amplitude IIS events that generalized across the three recording channels in Lox-Stop mice ([Figure 2A](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This finding demonstrates that IIS is a reproducible phenotype across different strains of mice with *Syngap1* haploinsufficiency. We quantified the frequency of IIS events during wakefulness in each genotype and found that spiking events were \~50 fold more frequent in mutants compared to WT controls ([Figure 2B](#fig2){ref-type="fig"}; [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). We also observed that high-amplitude IIS events in Lox-Stop animals exhibited state-dependence during Phase one recordings, with an \~18 fold higher frequency of these events observed during sleep compared to wakefulness ([Figure 2A,C](#fig2){ref-type="fig"}; [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}). We took advantage of the ability to re-express SynGAP protein in Lox-Stop mice to investigate how this strategy impacted IIS events. Remarkably, recordings during Phase II revealed that SynGAP re-expression in adult Lox-Stop mice eliminated IIS activity during wakefulness and sleep ([Figure 2A--B](#fig2){ref-type="fig"}). These data demonstrate that SynGAP protein dynamically regulates cellular mechanisms that govern systems-level excitability in the mature mouse forebrain.

![Rectification of state-dependent paroxysmal spiking events in *Syngap1* mutants after adult-initiated gene therapy.\
(**A**) Representative EEG/LFP traces from a WT \[Cre(+); +/+\] and *Syngap1* heterozygous mutant mouse \[Cre(+); +/ls\]. After initial recordings (pre-TMX), all animals were injected with TMX. Post-TMX recordings were acquired 30 days after the last TMX injection. TMX rescued low levels of SynGAP protein in +/ls animals (see [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Highlighted areas correspond to periods of sleep (see Materials and methods). Phase I and Phase II recordings are from the same animals. (**B**) Frequency of spiking events observed in the hippocampal LFP channel during the wake phase (i.e. non-highlighted areas in panel A) from both pre- and post-TMX recording sessions in each animal. Two-way repeated measures ANOVA.:Main genotype effects: F(1,11)=10.1, p=0.00879, Main TMX effects: F(1,11)=12.088, p=0.00518. Interaction between genotype and TMX: F(1,11)=9.777, p=0.00963. Cre(+);+/+n = 6, Cre(+);+/ls n = 7. (**C**) Comparison of the spiking frequency from the *h*LFP channel in Cre(+);+/ls mice during wake and sleep before TMX injections, paired-*t* test t(5)=-5.6007, p=0.002507 (n = 5). Data points in plots represent biological replicates (animals).\
10.7554/eLife.46752.009Figure 2---source data 1.Source data for [Figure 2B](#fig2){ref-type="fig"}.\
10.7554/eLife.46752.010Figure 2---source data 2.Source data for [Figure 2C](#fig2){ref-type="fig"}.](elife-46752-fig2){#fig2}

EEG waveforms are emerging as potential endpoints in clinical research studies for quantifying the efficacy of novel treatments for brain disorders ([@bib23]; [@bib35]). We were therefore interested in determining if EEG-recorded IIS events in *Syngap1* mice have parallels in humans expressing pathogenic *SYNGAP1* variants. While IIS events are commonly observed in both humans and animal models expressing genetic risk variants linked to epilepsy, worsening of these events during sleep is uncommon and is a symptom of a distinct cluster of epilepsy syndromes, such as electrical status epilepticus in sleep (ESES)/continuous spikes and waves during slow sleep (CSWS) ([@bib16]). Therefore, because sleep-dependent worsening of IIS events was observed in *Syngap1* mice, we searched for evidence of sleep-dependent worsening of paroxysmal spiking events in MRD5 patients. To do this, we mined data from a *SYNGAP1* patient registry, which has been used to uncover previously unreported phenotypes in this NDD population ([@bib33]). In this database, we found 11 entries that included a relatively complete medical history, including an EEG report from a neurologist and a detailed genetic report defining the *SYNGAP1* variant. Each of the selected patients was confirmed to have a severe *SYNGAP1* variant expected to cause genetic haploinsufficiency (i.e. heterozygous knockout caused by either a nonsense variant or a frameshift caused by an InDel). In each of these unique patient entries, there were clear references to IIS activity ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). However, there were six unique entries where the neurologist noted that spike-related events worsened during sleep. In one patient (\#5569), the neurologist noted that epileptiform activity was nearly constant during light sleep. In another (\#1029), IIS was observed in 30% of recorded sleep. Moreover, we obtained EEG recordings from two additional patients, S3-060 and S3-080, confirmed to express variants consistent with *SYNGAP1* haploinsufficiency. In these cases, we also observed evidence of sleep-dependent worsening of pathological EEG signals ([Figure 3A--D](#fig3){ref-type="fig"}). These clinical observations indicate that some patients with *SYNGAP1* haploinsufficiency have worsening EEG profiles during sleep, which strengthens the validity of sleep-dependent worsening of IIS in *Syngap1* mouse models.

![Representative EEG recordings taken from *SYNGAP1* patients during wake and sleep.\
Ten second epochs of electroencephalograms from patients with SYNGAP1 pathogenic variants. (**A**) Patient S3-060 while awake (**B**) Patient S3-060 while asleep (**C**) Patient S3-080 while awake (**D**) Patient S3-080 while asleep. Shaded areas indicate bursts of generalized epileptiform activity.](elife-46752-fig3){#fig3}

We next explored other measures of cognitive function impacted by SynGAP re-expression in adulthood. To date, only spontaneous alternation has been used to determine the impact of adult reversal of *Syngap1* pathogenicity on changes to cognitive function ([@bib6]). This measure of working memory was not improved after protein restoration in adult *Syngap1* Het mice. To expand cognitive-based testing of adult gene-restoration, we employed contextual fear conditioning, which requires animals to associate a novel context (e.g. the training environment) with an adverse event (e.g. mild foot-shock). Memory is inferred from a behavior change, such as freezing and/or immobility, when the animal is placed back in the training environment hours or days later. We, and others, have previously reported that *Syngap1* Het mice have normal expression of contextual fear 1 day (1d) after training ([@bib18]; [@bib36]). However, *Syngap1* Het mice display disrupted remote contextual memory because they have increased immobility when tested one month after training ([@bib39]). Thus, we focused on remote memory in this study. For these experiments, we used activity suppression ratios (ASR) to quantify behavioral performance rather than freezing. We did this because ASR is a well-validated measure of context fear and is reported to be a more reliable measure of context memory in mice with suspected differences in basal levels of detectable freezing ([@bib2]). Indeed, we have observed that the inclusion of the Cre-ER allele can cause intermittent, subtle twitching in mice during obvious bouts of freezing. This twitching behavior confounds automated measures of freezing. Here, we report that two different *Syngap1* Het strains (i.e. constitutive *Syngap1* Het mice and *Syngap1* Lox-Stop mice) exhibit a deficit in contextual memory deficit when tested 26-30d after training ([Figure 4A](#fig4){ref-type="fig"}; [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}; [Figure 4B](#fig4){ref-type="fig"}; [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). The first few days after contextual fear conditioning is marked by remote memory consolidation ([@bib15]), a systems-level process that involves communication between the hippocampus and the cortex and is believed to convert memory traces into a more permanent form of storage or maintenance. A selective deficit at remote time points is indicative of a systems memory consolidation deficit in *Syngap1* mice.

![Long-term memory can be improved in adult mice with *Syngap1* pathogenicity.\
(**A**) *Syngap1^+/+^* and *Syngap1^+/-^* ± were trained in the remote contextual fear conditioning paradigm and tested one month later for activity suppression levels. Activity of the *Syngap1^+/-^* was suppressed significantly less than that of the *Syngap1^+/+^* group indicating compromised remote memory for the mutant group. Unpaired *t* test (t(19)=-2.567, p=0.019). Cohen's d = 1.150. (**B**) *Syngap1^+/+^* and *Syngap1^+/ls^* mice were trained in the contextual fear conditioning paradigm and tested one month later for activity suppression levels. Activity of the *Syngap1^+/ls^* group was suppressed significantly less than that of the *Syngap1^+/+^* group indicating compromised remote memory for the mutant group. Wilcoxon rank sum test W = 19, p=2.82E-5, Cohen's d = 1.676. (**C**) *Syngap1^+/+^* and *Syngap1^+/-^* were tested, firstly, 1d after training, followed by another testing one month later. Activity suppression levels were not significantly different between the groups for either testing (unpaired t test,1-day t(13)=-0.033, p=0.974; 26 days t(13)=-1.068, p=0.305). (**D**) Experimental schematic depicting the breeding strategy for generation of Cre-inducible *Syngap1^Cre+;+/ls^* mice and Cre induction with TMX treatment for restoration of *Syngap1* expression and subsequent remote fear conditioning testing. (**E--F**) *Syngap1^Cre-;+/+^*, *Syngap1^Cre-;+/ls^*, *Syngap1^Cre+;+/+^*, and *Syngap1^Cre+;+/ls^* mice were run in the remote contextual fear conditioning paradigm without (**E**) and with (**F**) TMX administration. Activity suppression values from mice without TMX administration (**No TMX**) were assessed (2-factor ANOVA: Main Effects-Cre F(1,90)=0.030, p=0.864, Genotype F(1,91)=46.78, p=9.28E-10, Interaction F(1,91)=6.81, p=0.011; Cre- Cohen's d = 1.725, Cre+ Cohen's d = 0.910. **With TMX administration** (2-factor ANOVA: Main Effects- Cre F=(1,73)=0.019, p=0.891, Genotype F(1,73)=27.49, p=1.48E-6, Interaction F(1,73)=14.75, p=2.59E-4; Cre- Cohen's d = 2.167). Data points (and numbers) in bars represent biological replicates (animals). Data from panels E-F are pooled from at least two separate experiments.\
10.7554/eLife.46752.013Figure 4---source data 1.Source data for [Figure 4A](#fig4){ref-type="fig"}.\
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Upon further testing, we discovered that retrieval 1d after training prevented 26-30d remote memory deficits in *Syngap1* Hets ([Figure 4C](#fig4){ref-type="fig"}; [Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}). The retrieval-induced protection of remote memory in adult *Syngap1* animals suggested that the biological processes that promote systems consolidation may not be permanently damaged by heterozygosity of this gene during development. Therefore, we hypothesized that adult re-expression of SynGAP protein would improve the function of brain circuits that support remote memory. To do this, we again used the *Syngap1* Lox-Stop Het animal model that enables whole-body SynGAP protein re-expression beginning in adulthood. We trained adult offspring resulting from this cross in contextual fear conditioning and tested memory \~1 month after treatments with or without TMX ([Figure 4D](#fig4){ref-type="fig"}). In TMX(-) mice, we observed a strong main effect on genotype (i.e. the presence of Lox-Stop cassette; p=9.28E-10), but not with the presence of Cre-ER (p=0.864), which further supports the idea that *Syngap1* heterozygosity impacts remote memory ([Figure 4E](#fig4){ref-type="fig"}; [Figure 4---source data 4](#fig4sdata4){ref-type="supplementary-material"}). We observed a relatively weak statistical interaction between Cre-ER and Lox-Stop (p=0.011). Importantly, pairwise comparisons among all four groups indicated that both Cre(-) and Cre(+) *Syngap1* Hets performed significantly differently compared to corresponding *Syngap1* WT controls ([Figure 4E](#fig4){ref-type="fig"}; [Supplementary file 4](#supp4){ref-type="supplementary-material"}; [Figure 4---source data 5](#fig4sdata5){ref-type="supplementary-material"}). There was also no difference in performance between Cre(-) and Cre(+) *Syngap1* Hets ([Figure 4E](#fig4){ref-type="fig"}; [Supplementary file 4](#supp4){ref-type="supplementary-material"}), indicating that Cre remained sufficiently inactive in the absence of TMX in these mice.

In TMX(+) studies ([Figure 4F](#fig4){ref-type="fig"}), we again observed a strong main effect on genotype (p=1.48E-6), but not with the presence of Cre-ER (p=0.891). In contrast to TMX(-) studies, here we observed a highly significant interaction between Cre-ER and Lox-Stop (p=2.59E-4), which suggested that SynGAP re-expression altered activity suppression levels. Pairwise comparisons of all four genotypes indicated that elevated ASR levels normally found in *Syngap1* haploinsufficient mice were reversed back to WT levels by TMX injections. For example, TMX-treated Cre(+) *Syngap1* Het mice were no different from corresponding Cre(+) WT *Syngap1* mice ([Figure 4F](#fig4){ref-type="fig"}; [Supplementary file 4](#supp4){ref-type="supplementary-material"}). Moreover, the ASR in these mice was significantly reduced compared to Cre(-) *Syngap1* Lox-Stop Hets \[i.e. mice with preserved *Syngap1* pathogenicity), consistent with adult reversal of the remote memory deficit ([Figure 4F](#fig4){ref-type="fig"}; [Supplementary file 4](#supp4){ref-type="supplementary-material"}). It is important to note that while we did not observe any main effects of Cre-ER in either TMX(-) or TMX(+) studies, there is a trend for Cre-ER to increase ASR in WT mice (i.e. mice without the Lox-Stop allele) across both experiments. However, we conclude that this trend did not confound the interpretation of how gene restoration impacted behavioral performance in this experiment. To the contrary, the trend for Cre-ER to increase ASR in WT mice was actually reversed when comparing Cre(-) and Cre(+) Lox-Stop mice ([Figure 4F](#fig4){ref-type="fig"}). We interpreted this as further evidence that SynGAP re-expression improved performance in the memory task. Taken together, these data support the interpretation that SynGAP re-expression in adulthood rescues remote contextual memory deficits in *Syngap1* haploinsufficient mice.

Next, we directly tested the idea that *Syngap1* gene restoration improves the function of neural circuits that promote systems-memory consolidation. Hippocampal oscillations are linked to a range of cognitive functions, including various mnemonic processes associated with systems memory consolidation ([@bib8]). Therefore, we recorded hippocampal oscillations through an LFP electrode implanted in CA1. We recorded these signals in mice both before and after *Syngap1* gene restoration, which enabled us to assess how this therapeutic strategy impacted hippocampal function in each animal. Theta rhythms were clearly observable in WT mice during both recording phases ([Figure 5A](#fig5){ref-type="fig"}). However, in recordings from Lox-Stop mice during Phase I, theta rhythms often appeared less robust during periods of free exploration compared to WT littermates ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). After SynGAP re-expression, theta oscillations in these animals increased compared to pre-injection baseline recordings ([Figure 5B](#fig5){ref-type="fig"}). Across the entire Lox-Stop population, we found that theta-range signal amplitude was significantly enhanced by raising SynGAP protein levels in this population of adult Lox-Stop mice ([Figure 5C](#fig5){ref-type="fig"}), which is a finding consistent with improved performance in memory tasks considering that increased theta rhythm expression has been shown to correlate with better memory performance.

![Increased amplitude of theta oscillations after SynGAP re-expression in adult *Syngap1* mutant mice.\
(**A--B**) CA1 LFP traces from a WT (**A**) and a *Syngap1* mutant (**B**) mouse during Phase I and Phase II sessions. (**C**) Grand average of within-subjects changes in signal amplitude across the full spectrum of hippocampal rhythms. The amplitude change was normalized by the average amplitude during Phase I sessions. The shaded areas represent 95% bootstrapped confidence intervals. Significant increases in amplitude in Phase II were detected in the 6--12 Hz theta range (Permutation test: p=0.0128, 5000 shuffles). N's are biological replicates (animals). Legends for Figure Supplements.](elife-46752-fig5){#fig5}

Theta rhythms in mice are modulated by running speed ([@bib17]) and it has been reported that *Syngap1* Het mice are hyperactive in some, but not all, contexts ([@bib26]). Therefore, we tracked locomotor activity in all recorded mice across both sessions to determine if phase-specific changes in activity levels may have contributed to changes in theta amplitude ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}; [Figure 5---figure supplement 2---source data 1](#fig5s2sdata1){ref-type="supplementary-material"}). Similar to past studies, Cre(+) Lox-Stop Het mice were hyperactive compared Cre(+)WT controls as evidenced by a significant main effect of genotype (i.e. group) on distance traveled (p=0.002). However, we did not observe an effect of phase (p=0.692), or an interaction between phase and genotype in this analysis (p=0.085). Therefore, the phase-independent increases in locomotor activity in Het mice are unlikely to explain the phase-specific changes to theta rhythms in these animals.

Discussion {#s3}
==========

The principal finding in this study is that genetic reversal of *Syngap1* pathogenicity in adult mice reverses deficits in remote memory, lowers seizure threshold, re-balances neural excitability, and improves hippocampal/cortical function. On the surface, these exciting results are somewhat paradoxical given that we have previously found that *Syngap1* pathogenicity causes hardwired impairments in the development of forebrain circuits that mediate a subset of previously tested cognitive functions ([@bib6]; [@bib1]; [@bib40]). These previous studies indicated that impaired assembly of forebrain circuits contribute to life-long impairments in brain function because a set of behaviors were shown to be resistant to adult re-activation of SynGAP protein expression. How then can these current findings be reconciled with past findings demonstrating that certain behavioral paradigms are not sensitive to adult re-expression of SynGAP protein? The most parsimonious explanation is that not all behavioral impairments common to the *Syngap1* endophenotype are governed by hardwired circuit changes, which in turn reflect altered neurodevelopmental processes. Some behavioral impairments may be caused by altered 'real-time' neuronal signaling that is not restricted to defined periods of neurodevelopment ([@bib54]). Elegant work in *Shank3* mouse models directly supports this interpretation ([@bib32]). Feng and colleagues demonstrated that adult reversal of *Shank3* pathogenicity improved some non-cognitive and non-seizure-related behavioral phenotypes, while other independent phenotypes remained completely impaired even though protein levels were restored to WT levels. Restoring Shank3 protein levels early in development prevented the emergence of adult reversal-resistant behavioral impairments, indicating that low expression of germline Shank3 protein disrupts both developmental and non-developmental cellular processes.

Evidence in the literature indicates that *Syngap1* may have unique functions during both development and adulthood, which supports an evolving interpretation of SynGAP function in the brain. For instance, *Syngap1* heterozygosity causes a transient increase in baseline postsynaptic function in CA1 Schaffer collateral synapses during postnatal development ([@bib6]). This is a true developmental impact of *Syngap1* pathogenicity because inducing pathogenicity in adulthood does not induce a change in baseline excitatory synapse function in hippocampal synapses. Interestingly, baseline excitatory function of this pathway normalizes by adolescence, as evidenced by several groups ([@bib27]; [@bib28]), including our own ([@bib6]), reporting normal postsynaptic baseline function in this synapse in mature animals. However, there is a dramatic impairment in LTP stability at these synapses in adult *Syngap1* mice ([@bib27]; [@bib28]). This function of *Syngap1* appears unrelated to neurodevelopment because LTP can be completely rescued after adult re-expression of low SynGAP protein levels ([@bib39]). Thus, *Syngap1* exhibits both developmental and non-developmental functions within the same synapses in the hippocampus. As a consequence, not all deficits related to neuronal function in the adult *Syngap1* Het mouse brain can be attributed to hardwired circuit damage caused by impaired neurodevelopment.

The real-world impact of our current findings is two-fold. First, therapies that improve the expression and/or function of SynGAP protein may be beneficial to MRD5 patients of all ages. Adult re-expression of SynGAP appears to correct neurophysiological imbalances within circuits that predispose the brain to seizure generation and certain forms of cognitive impairment. Therefore, the impact of therapies related to elevated SynGAP levels in adult patients could be significant. It remains unclear if adult re-expression of SynGAP corrects seizure susceptibility and memory impairments through a common mechanism. Future studies will be necessary to determine the molecular and cellular mechanisms that are recovered in the forebrain after SynGAP re-expression. Moreover, it will be critical to link these recovered molecular and cellular processes to circuit-level processes that directly contribute to behavioral memory and seizure. This type of experimental strategy may help to elucidate novel neural circuit correlates of behavioral alterations and excitability impairments associated with NDDs. However, early therapeutic intervention should remain the primary NDD treatment strategy. Treatments during development would protect the brain from both hardwired circuit damage caused by disruptions to critical neurodevelopmental processes ([@bib6]; [@bib1]; [@bib7]) and 'real-time' age-independent neurophysiological imbalances described in this study.

The second real-world implication of this study is that it may have identified a candidate translatable biomarker that can serve as an endpoint for efficacy testing of novel treatments for MRD5 patients. Our data indicate that IIS events appear to worsen during sleep in both humans and mice with *SYNGAP1/Syngap1* haploinsufficiency. Sleep-linked worsening of IIS is a hallmark of epilepsy syndromes with significant cognitive impairment ([@bib16]). Similar to what we report here, a recent, comprehensive analysis of a cohort of *SYNGAP1* patients observed a sleep-dependent increase in pathological EEG waveforms in approximately half of the children ([@bib49]). We found that SynGAP re-expression in adult mutant mice eliminated these pathological events, which are also detected by EEG electrodes, during both wakefulness and sleep. Considering that this treatment strategy also improved measures of behavioral seizure and memory, the severity of IIS during sleep may be a predictor of generalized cortical impairment associated with *SYNGAP1* pathogenicity. If a relationship between the severity of state-dependent IIS and cognitive impairment is observed in patients, then these signals may be useful as biomarkers for improved cortical function in translational studies aimed at identifying effective therapeutic strategies for *SYNGAP1* patients.

Materials and methods {#s4}
=====================

Animals and behavior {#s4-1}
--------------------

*Syngap1* constitutive (*Syngap1*^+/-^; RRID: [MGI:3576223](https://scicrunch.org/resolver/MGI:3576223)) and reversal (*Syngap1*^+/ls^; RRID:[MGI:5469866](https://scicrunch.org/resolver/MGI:5469866)) mice were constructed and maintained as previously described ([@bib39]). Inducible CAGG-Cre-ER male mice (RRID: [MGI:2182767](https://scicrunch.org/resolver/MGI:2182767)) were purchased from Jackson Laboratories (JAX stock \#004682) and crossed to female *Syngap1*^+/ls^ for adult reversal studies. Male and female experimental mice were utilized for all studies. Animals were group housed (n = 4/cage) by sex and otherwise randomly assigned to cages yielding mixed genotypes. Moreover, each cohort of mice was represented by multiple litters. Animals were kept on a normal light-dark cycle and had free access to food and water. Animal experiments were conducted according to protocols submitted to, and approved by, Scripps Research (Protocol \#15--037 and \#15--038) and the Baylor College of Medicine (Protocol \#AN5585) Institutional Animal Care and Use Committees.

Mice (PND90-120) were handled for several minutes on three separate days prior to commencement of behavioral testing. Tails were marked for easy identification and access from home cages during testing. Various cohorts of mice were utilized in this study consisting of one or two cohorts of naïve *Syngap1^+/ls^* mice for the TMX(-) flurothyl-induced seizure and remote fear conditioning experiments, respectively and two other cohorts of *Syngap1^+/ls^* mice for both the fear conditioning and seizure TMX(+) experiments. Several mice from the TMX(+) inducible Cre cohorts were unhealthy or died prior to testing, so we ran two cohorts for the TMX(+) experiments. One naïve cohort of non-inducible *Syngap1* constitutive or lox/stop mice were used for the other fear conditioning experiments in [Figure 4A--C](#fig4){ref-type="fig"}. Samples sizes for *Syngap1*-related studies in our lab have been estimated using GPower 3.0. Estimates for effect size and variance of behavioral data were based on published studies using the *Syngap1* mouse lines ([@bib6]; [@bib1]; [@bib39]; [@bib18]). Experimenters were blind to genotype while conducting behavioral tests and during data analysis.

Cre Induction {#s4-2}
-------------

TMX (Sigma T5648, St. Louis, MO) was prepared in corn oil containing 10% EtOH to a final TMX dosage of 100 mg/kg, injectable concentration of 20 mg/ml, and volume of 5 ml/kg and administered (intraperitoneal) once a day for five consecutive days starting at PND60.

*Contextual fear conditioning:* A dedicated fear conditioning room in the TSRI Florida Mouse Behavior Core contains four fear conditioning apparati that can be used in parallel. Each apparatus was an acrylic chamber measuring approximately 30 × 30 cm (modified Phenotyper chambers, Noldus, Leesburg, VA). The top of the chamber is covered with a unit that includes a camera and infrared lighting arrays (Noldus, Ethovision XT 11.5, Leesburg, VA) for monitoring of the mice. The bottom of the chamber is a grid floor that receives an electric shock from a shock scrambler that is calibrated to 0.40 mA prior to experiments. The front of the chamber has a sliding door that allows for easy access to the mouse. The chamber is enclosed in a sound-attenuating cubicle (Med Associates) equipped with a small fan for ventilation. Black circular, rectangular and white/black diagonal patterned cues were placed outside each chamber on the inside walls of the cubicles for contextual enhancement. A strip light attached to the ceilings of the cubicles provided illumination. A white noise generator (\~65 dB) was turned on and faced toward the corner of the room between the cubicles. The fear conditioning paradigm consisted of two phases, training, followed by testing 1 and 26, or 30 d thereafter. The 4.5 min training phase consisted of 2.5 min of uninterrupted exploration. Two shocks (0.40 mA, 2 s) were delivered, one at 2 min 28 s, the other at 3 min and 28 s from the beginning of the trial. During testing, mice were placed into their designated chambers and allowed to roam freely for 5 min. Immobility durations (s) and activity (distances moved (cm)) during training and testing were obtained automatically from videos generated by Ethovision software. Activity suppression ratio levels were calculated: 0--2 min activity during testing/0--2 min activity during training +testing.

Flurothyl-induced seizures {#s4-3}
--------------------------

Flurothyl-induced seizure studies were performed based on prior studies with some modifications ([@bib6]; [@bib39]; [@bib12]). Briefly, experiments were conducted in a chemical fume hood. Mice were brought to the experimental area at least 1 hr before testing. To elicit seizures, individual mice were placed in a closed 2.4 L Plexiglas chamber and exposed to 99% Bis (2,2,2-triflurothyl) ether (Catalog\# 287571, Sigma-Aldrich, St. Louis, MO). The flurothyl compound was infused onto a filter paper pad, suspended at the top of the Plexiglas chamber through a 16G hypodermic needle and tube connected to a 1 ml BD glass syringe fixed to an infusion pump (KD Scientific, Holliston, MA, USA, Model: 780101) at a rate of 0.25 ml/min. The infusion was terminated after the onset of a hind limb extension that usually resulted in death. Cervical dislocation was performed subsequently to ensure death of the animal. Seizure thresholds were measured as latency (s) from the beginning of the flurothyl infusion to the beginning of the first myoclonic jerk (1 st clonus), then to generalized tonic/clonic seizure (T/C), and finally to total hind limb extension (THE).

Immunoblotting {#s4-4}
--------------

Western blot analysis was performed on protein lysates extracted from the hippocampi of adult mice and dissected in ice-cold PBS containing Phosphatase Inhibitor Cocktails 2 and 3 (Sigma-Aldrich, St. Louis, MO) and Mini-Complete Protease Inhibitor Cocktail (Roche Diagnostics) and immediately homogenized in RIPA buffer (Cell Signaling Technology, Danvers, MA). Sample protein concentrations were measured (Pierce BCA Protein Assay Kit, Thermo Scientific, Rockford, IL), and volumes were adjusted to normalize microgram per microliter protein content. 10 μg of protein per sample were loaded and separated by SDS-PAGE on 4--15% gradient stain-free tris-glycine gels (Mini Protean TGX, BioRad, Hercules, CA), transferred to low fluorescence PVDF membranes (45 μm) with the Trans-Blot Turbo System (BioRad). Membranes were blocked with 5% powdered milk in buffer and probed with pan-SynGAP (1:10,000, PA1-046, Pierce/Thermo Scientific) overnight at 4°C and HRP-conjugated anti-rabbit antibody (1:2,500, W4011, Promega) for 1 hr at room temperature followed by ECL signal amplification and chemiluminescence detection (SuperSignal West Pico Chemiluminescent Substrate; Thermo Scientific, Rockford, IL). Blot band densities were obtained using the Alpha View imaging system (Alpha Innotech). SynGAP levels of immunoreactivity were assessed by densitometric analysis of generated images with ImageJ. Values were normalized to total protein levels obtained from blots prior to antibody incubations.

Video-EEG recordings from mice {#s4-5}
------------------------------

Experiments were carried out on Cre(+)/*Syngap1* Lx-ST heterozygous mice and littermate Cre(+)/*Syngap1* WT controls. Experimenters were blind to the genotypes. Animals were bred at The Scripps Research Institute and experimental mice transferred to Baylor College of Medicine at \~4--5 weeks of age. Animals at 11 weeks of age were secured on a stereotaxic frame (David Kopf) under 1--2% isoflurane anesthesia. Each mouse was prepared under aseptic condition for the following recordings: Teflon-coated silver wires (bare diameter 127 µm, A-M systems) were implanted bilaterally in the subdural space of the somatosensory cortex ([@bib42]) (0.8 mm posterior, 1.8 mm lateral to bregma) with reference to the midline over the cerebellum) for cortical EEG as well as in neck muscles for electromyogram recordings to monitor mouse activity. An additional electrode constructed with Teflon-coated tungsten wire (bare diameter 50 µm, A-M systems) was stereotaxically implanted in the CA1 of the hippocampus ([@bib42]) (1.9 mm posterior, 1.0 mm lateral, and 1.3 mm ventral to bregma) with reference to the ipsilateral corpus callosum for local field potential recordings. All electrode wires and the attached miniature connector sockets were fixed to the skull by dental cement. After 2 weeks of post-surgical recovery, mice received Phase I video-EEG recordings (2 hr per day for 3 days). Signals were amplified (100x) and filtered (bandpass, 0.1 Hz - 1 kHz) by 1700 Differential AC Amplifier (A-M Systems), then digitized at 2 kHz and stored on disk for off-line analysis (DigiData 1440A and pClamp10, Molecular Devices). Time-locked mouse behavior was recorded by ANY-maze tracking system (Stoelting Co.). In addition, manual ON/OFF camcorder was used to monitor the behavior at higher resolution. Beginning the day after Phase I recordings of video-EEG, all mice received daily injections of Tamoxifen (*as above*) for 5 days. One month later, these mice were subjected to Phase II video-EEG recordings (three 2 hr sessions over 3 days) under the same settings as in Phase I. At the end of the experiments, mice were euthanized, and hippocampi were dissected to determine the efficacy of SynGAP protein re-expression.

High-Amplitude interictal spike quantification {#s4-6}
----------------------------------------------

Axograph3 or pClamp10 software (Molecular Devices, San Jose, CA) was used to detect high-amplitude spiking events. The threshold was set at +1 mV in the CA1 depth channel for all animals and all events that exceeded the threshold were logged. Events were occasionally rejected as 'non-physiological'. These rejected signals were identified by their usually high signal amplitude and time-locked peaks in more than one channel and their atypical shape compared to paroxysmal spikes. Behavioral epochs were segregated into sleep and wake phases. Sleep was inferred from an abrupt quieting of the EMG signal and confirmation of immobility from time-locked videos. Experimenters were blind to genotype while conducting spike quantification analyses.

Analysis of hippocampal oscillations {#s4-7}
------------------------------------

Analyzes focused on the first 10 min of each recording session for each mouse to account for experience-dependent changes in mouse hippocampal rhythms ([@bib17]). Videos of mouse behavior and EMG recordings were used to verify that mice were engaged in active locomotion during this period, considering that theta oscillations occur most prominently in the hippocampus during voluntary movement ([@bib48]). Time-resolved amplitudes of CA1 LFP recordings were estimated using a complex Morlet wavelet transform with a width parameter of six periods, evaluated at 50 frequencies logarithmically spaced between 1 and 100 Hz ([@bib47]). Wavelets were normalized such that their area under the curve was equal to one ([@bib30]). The magnitude of theta (6--12 Hz) oscillations across time was quantified using the ratio of theta to delta (1--4 Hz) power. The power ratio was smoothed by a moving average time window of 1 s. The one-second time window with the highest theta-delta power ratio for each mouse in each Phase was selected for the representative CA1 LFP recordings shown in [Figure 5A & B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. To account for the variability of theta amplitudes across mice (see [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), amplitude changes between Phase I and Phase II sessions were calculated within each mouse and then normalized by the corresponding amplitude during Phase I sessions ([Figure 5C](#fig5){ref-type="fig"}). Experimenters were blind to genotype while conducting LFP analyses.

Human subject data {#s4-8}
------------------

Collection of human subject data was reviewed and approved by Hummingbird (Study \# 2016--57-SYNGAP) and Baylor College of Medicine (Study \#H-30480 and \#H-41411) Institutional Review Boards.

Collection and analysis of data from the retrospective SYNGAP1 natural history study registry {#s4-9}
---------------------------------------------------------------------------------------------

The *SYNGAP1* Patient Registry ([@bib33]; <https://syngap1registry.iamrare.org>) is funded through the National Organization of Rare Disorders. This study was Institutional Review Board (IRB)-approved and meets all relevant ethical regulations for protections for human subjects. It is actively managed by a board of trustees comprised of a team of seven stakeholders, including parents with affected children, clinician-scientists that care for MRD5 patients, and neurobiologists that study the gene. The *SYNGAP1* (MRD5) Natural History Study Registry is a retrospective longitudinal web-based observational natural history study. Parents or guardians provided informed consent prior to depositing medical history data into the registry. Participants with *SYNGAP1* (MRD5) will be followed throughout the course of their lives with either the participant or authorized respondents contributing data at varying intervals throughout the course of the study. Initially, when a new patient is registered, data are collected on demographics, quality of life, medical history including genetic reports, disease phenotypes, event episodic data, retrospective data, participant-review of systems, medication, and diagnostic data. Each registrant is given a unique identifier to facilitate anonymization of patient data. Initial data collection is done through a series of questionnaires, including a survey of sensory and sensory-related issues. The structure of the database and all questionnaires were reviewed and approved by the members of the Board of Trustees.

To acquire information about EEG during sleep and wakefulness in the *SYNGAP1* patient population, the registry database was queried for all entries that: 1) had a detailed genetic report that confirmed the presence of a severe *SYNGAP1* loss-of-function variant likely to induce genetic haploinsufficiency; 2) had at least a narrative report from a neurologist that discussed the findings of an EEG study. [Supplementary file 3](#supp3){ref-type="supplementary-material"} summarizes each patient-specific *SYNGAP1* variant and findings from their EEG study. A subset of EEG reports contained information about the patients' overall clinical presentations and medications at the time of their EEG study. This information was included in [Supplementary file 3](#supp3){ref-type="supplementary-material"} where appropriate.

Human EEG {#s4-10}
---------

The parents of patients S3-060 and S3-080, which are distinct patients from those represented in [Supplementary file 3](#supp3){ref-type="supplementary-material"}, provided written informed consent according to a protocol approved by the Baylor College of Medicine Institutional Review Board. The medical record and genetic reports were reviewed by a board-certified neurologist. Patient S3-060 was determined to harbor a pathogenic *SYNGAP1* variant \[c.1154-1161del (p.S385fs)\] as was patient S3-080 \[c.3190 C \> T (p.Q1064X)\]. Each patient had a scalp electroencephalogram with a minimum of 21 electrode recordings in a standard 10--20 distribution and a minimum of 45 min of recording which were reviewed by board-certified neurophysiologists as part of clinical care. The electroencephalograms were further manually reviewed by a board-certified neurologist (JLH) and representative epochs were captured.

Statistics {#s4-11}
----------

Statistical tests for mouse seizure and fear conditioning data were conducted using SPSS and R packages importing Excel files containing raw data. Based on our prior experience with these behaviors, a general parametric statistical approach was used to assess data sets. Unpaired t tests for experiments with two groups comparing genotypes and two-factor ANOVAs with Bonferroni pair-wise comparisons for experiments with four groups assessing contingencies of Cre and genotype factors were performed to assess activity suppression ratio values associated with fear conditioning. MANOVAs were performed to assess Cre/genotype contingencies for the multiple levels of factors associated with seizure threshold (1^st^ clonic, T/C, and THE). In behavioral studies, we included *Cohen's d* for *Syngap1*^+/+^ vs. *Syngap1*^+/(-)or(ls)^ as a measure of effect size when means were found to be significant between relevant groups. Explorations of data sets showed reasonably normal distributions and homogeneity of variances as assessed by Levene's test for equality of variances as well as Box's test for equality of covariance matrices. A nonparametric permutation test (5000 shuffles) was used to assess differences in oscillatory activity.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000026National Institute on Drug Abuse T32DA01892 to Ernie Hwaun.

-   http://dx.doi.org/10.13039/100000065National Institute of Neurological Disorders and Stroke Mentored Clinical Scientist Research Career Development Award NS091381 to Jimmy Lloyd Holder.

-   Robbins Foundation to Jimmy Lloyd Holder.

-   http://dx.doi.org/10.13039/100000065National Institute of Neurological Disorders and Stroke NS100738 to Jianrong Tang.

-   http://dx.doi.org/10.13039/100000025National Institute of Mental Health MH102450 to Laura L Colgin.

-   http://dx.doi.org/10.13039/100000025National Institute of Mental Health MH105400 to Courtney A Miller.

-   http://dx.doi.org/10.13039/100000026National Institute on Drug Abuse DA034116 to Courtney A Miller.

-   http://dx.doi.org/10.13039/100000026National Institute on Drug Abuse DA036376 to Courtney A Miller.

-   http://dx.doi.org/10.13039/100000025National Institute of Mental Health MH108408 to Gavin Rumbaugh.

-   http://dx.doi.org/10.13039/100000025National Institute of Mental Health MH096847 to Gavin Rumbaugh.

-   http://dx.doi.org/10.13039/100000065National Institute of Neurological Disorders and Stroke NS064079 to Gavin Rumbaugh.

This work was supported in part by NIH grants from the National Institute of Mental Health \[MH096847 and MH108408 (GR), MH105400 (CAM), MH102450 (LLC)\], the National Institute of Neurological Disorders and Stroke \[NS064079 (GR), NS100738 (JT)\], and the National Institute on Drug Abuse \[DA034116 and DA036376 (CAM), T32DA01892 (EH)\]. JLH is supported by a National Institute of Neurological Disorders and Stroke Mentored Clinical Scientist Research Career Development Award \[NS091381\] and the Robbins Foundation. The video-EEG experiments were performed by the IDDRC Neuroconnectivity Core at Baylor College of Medicine.

Additional information {#s5}
======================

Reviewing editor, *eLife*.

No competing interests declared.

Formal analysis, Investigation, Methodology, Writing---review and editing.

Formal analysis, Investigation, Writing---review and editing.

Formal analysis, Writing---review and editing.

Investigation, Visualization, Methodology, Writing---review and editing.

Formal analysis, Investigation, Writing---review and editing.

Formal analysis, Investigation, Writing---review and editing.

Investigation, Methodology, Writing---review and editing.

Investigation, Methodology, Writing---review and editing.

Investigation, Methodology, Writing---review and editing.

Investigation, Methodology, Writing---review and editing.

Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing---original draft.

Human subjects: The SYNGAP1 Patient Registry \[42\] (https://syngap1registry.iamrare.org) is funded through the National Organization of Rare Disorders. Collection of human subject data was reviewed and approved by Hummingbird (Study \# 2016-57-SYNGAP) and Baylor College of Medicine (Study \#H-30480 and \#H-41411) Institutional Review Boards. The parents of patients S3-060 and S3-080, which are distinct patients from those represented in Supplementary File 3, provided written informed consent according to a protocol approved by the Baylor College of Medicine Institutional Review Board.

Animal experimentation: Animal experiments were conducted according to protocols submitted to, and approved by, Scripps Research (Protocol \#15-037 and \#15-038) and the Baylor College of Medicine (Protocol \#AN5585) Institutional Animal Care and Use Committees.

Additional files {#s6}
================

10.7554/eLife.46752.022

###### Pairwise comparison statistics for [Figure 1](#fig1){ref-type="fig"}.

Pairwise comparisons for each of the four groups in data presented in [Figure 1A--B](#fig1){ref-type="fig"}.

10.7554/eLife.46752.023

###### Pairwise comparison statistics for [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

Pairwise comparisons for each of the four groups in data presented in [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}.

10.7554/eLife.46752.024

###### Summary of EEG data from MRD5 patients in the *SYNGAP1* Registry.

Subset of entries from the *SYNGAP1* patient registry noting EEG abnormalities.

10.7554/eLife.46752.025

###### Pairwise comparison statistics for [Figure 4E--F](#fig4){ref-type="fig"}.

Pairwise comparisons for each of the four groups in data presented in [Figure 4E--F](#fig4){ref-type="fig"}.

10.7554/eLife.46752.026

Data availability {#s7}
=================

Data used for generating figures are included in the manuscript and supporting files.

10.7554/eLife.46752.028

Decision letter

Westbrook

Gary L

Reviewing Editor

Vollum Institute

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Adult Reversal of Memory and Excitability Impairments in a Model of Syngap1 Pathogenicity\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Gary Westbrook as the Senior and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Mary B Kennedy (Reviewer \#1). Two other reviewers remain anonymous.

As you will see from the reviewers\' comments, they accepted the conclusions of the work but thought that its impact was modest at this stage given that similar observations have been made for other neurodevelopment disorders, and that the mechanistic distinction between Syngap 1 early deficits and those that were reversible in the adult are not further explored here. Thus we think the manuscript at this stage is better suited to a more specialized journal.

*Reviewer \#1:*

The study by Creson et al. adds to previous work from the Rumbaugh lab on behavioral effects of synGAP haploinsufficiency. The new work shows that cognitive deficiency measured by the long-term contextual fear memory paradigm can be reversed by re-expression of a full complement of synGAP in adulthood. This finding is in contrast to their earlier finding regarding cognition measured by spontaneous alternation in a T-maze paradigm, which is believed to measure working memory. Earlier work from the Rumbaugh lab had shown that haploinsufficient mice are deficient in the alternation task, and the deficiency is not restored by re-expression of synGAP in adulthood. In that study, the authors, apparently over-generalized prematurely, by concluding that \"repairing the pathogenic mutations in adulthood did not improve behavior and cognition.\"

In the present study, the authors further show that reduced seizure threshold produced by synGAP haploinsufficiency is reversed by re-expression in adulthood.

The study is important because it indicates that the seizure susceptibility and certain aspects of cognitive disability that accompany synGAP haploinsufficiency may be improved by correcting the defect in adulthood. The study leads to the interesting question: Which behavioral tasks are \"permanently\" damaged by the disruption of critical periods caused by synGAP haploinsufficiency, and which behavioral tasks are not \"permanently\" damaged? The answer could shed light on which brain functions can be affected by ongoing brain plasticity in adulthood.

The study appears well executed. The only major weakness of the manuscript is a lack of clarity resulting from over-generalization of results, and/or from the absence of important experimental details that should be supplied for the general readership of *eLife*.

In the Introduction, the authors again show a tendency to overgeneralize from very specific results by stating that historically, pathology leading to neurodevelopmental disorders was thought to arise exclusively from impaired brain development. They then cite several studies of particular disorders around 2008 that led to the \"revolutionary idea\" that \"therapeutic intervention may be beneficial in adult NDD patients with fully mature brains.\" The authors should make the introductory paragraph more accurate, and more useful, by referring to the specific disorders (i.e. Rett Syndrome and tuberous sclerosis) for which improvement after treatment of adults was noted. It seems clear that some NDD\'s will not be improved by treatment in adulthood; whereas others may be. It is confusing, especially to the general readership of a journal like *eLife*, to repeatedly generalize from a few cases to all cases.

The phrase, \"critical period that is essential for the assembly and excitatory balance of developing forebrain circuits\" is obscure. I believe the authors mean -- the \" critical period during which a normal ratio of excitatory and inhibitory synapses are formed in particular brain regions. Without this normal ratio, the circuits can become overly excitable, leading to pathological function.\"

At the beginning of the Discussion, the authors state, \"The principle finding of this study is that genetic reversal of Syngap1 pathogenicity in adult mice improves deficits in memory and excitability.\" This is another overgeneralization that is potentially confusing. The authors should state, \"The principal finding of this study is that genetic reversal of Syngap1 pathogenicity in adult mice improves deficits in long-term contextual memory and in seizure thresholds.\" In the next sentence, the authors should change the ending; \"... that mediate working memory.\" The paradox that the authors refer to arises solely from their own overgeneralization. The significance of the authors work would be more broadly accepted if they refrained from over-generalization in the first place.

*Reviewer \#2:*

In this manuscript, the authors show that Syngap1 heterozygous knockout mice exhibit impaired remote memory for contextual fear when tested 30 days after training, despite having normal contextual memory when tested 1 day after training. Interestingly, the authors crossed Syngap1 Lox-stop heterozygous mice to hemizygous tamoxifen-inducible Cre mice and show that re-expressing Syngap1 in adult mice reversed the remote memory deficit. The authors proceed to demonstrate that seizure threshold, but not sensorimotor gating, phenotypes are reversed by re-expressing Syngap1 in adults. The authors conclude that genetic reversal of Syngap1 pathogenicity in adult can improve impaired cognition altered excitability.

The findings are interesting, but I am not sure whether they rise to the level of importance and novelty to warrant being published as a short report in *eLife*. As noted by the authors, similar findings in other mouse models of intellectual disability/autism spectrum disorder have demonstrated and in this manuscript there are no experiments designed to get at the mechanism or brain region where re-expression of Syngap1 is exerting this effect in adulthood. In addition, there is an interesting finding that is not explained: there is no remote memory phenotypes if the Syngap1 heterozygous mutant mice are tested one day after training, suggesting the retrieval of the memory prevents the remote memory impairment. How is does this observation impact the interpretation of the remote memory phenotype?

In closing, although the findings are interesting and potentially important for understanding pathologies in adult Syngap1 mutant mice, I am not sure that they warrant publication in *eLife*.

*Reviewer \#3:*

The manuscript by Thomas Creson et al. reported that re-expression in adults can reverse some behavioral and seizure abnormalities even though SynGAP loss disrupts neurodevelopment. Specifically, the authors showed evidence that 1) re-expression of SynGAP in adults reverses remote memory deficit in a SynGap1 Het mice with 50% SynGAP loss; 2) re-expression of SynGAP in adults also alleviates seizures in SynGap1 Het mice. These findings are interesting and worth publishing but they do not reach the level of significance expected for *eLife*. The seizures and remote memory phenotypes are very interesting, but they remain mostly unexplored in this manuscript. The finding that it is possible to reverse in adults certain behavioral and physiological phenotypes in neurodevelopmental mouse mutants is interesting and clinically relevant, but it is not novel, since it has been demonstrated repeatedly in multiple neurodevelopmental conditions.

10.7554/eLife.46752.029

Author response

\[Editors' note: the manuscript was revised and accepted after re-review.\]

Reviewer \#1:

> \[...\] The study appears well executed. The only major weakness of the manuscript is a lack of clarity resulting from over-generalization of results, and/or from the absence of important experimental details that should be supplied for the general readership of eLife.

*In the Introduction, the authors again show a tendency to overgeneralize from very specific results by stating that historically, pathology leading to neurodevelopmental disorders was thought to arise exclusively from impaired brain development. They then cite several studies of particular disorders around 2008 that led to the \"revolutionary idea\" that \"therapeutic intervention may be beneficial in adult NDD patients with fully mature brains.\" The authors should make the introductory paragraph more accurate, and more useful, by referring to the specific disorders (i.e. Rett Syndrome and tuberous sclerosis) for which improvement after treatment of adults was noted. It seems clear that some NDD\'s will not be improved by treatment in adulthood; whereas others may be. It is confusing, especially to the general readership of a journal like eLife, to repeatedly generalize from a few cases to all cases.*

We have rewritten the Introduction based on the comments of the reviewer. We now draw a distinction between the earlier modeling work on syndromic risk factors that impact the whole body, and our newer work, which deals with the biology of risk factors that principally cause severe NDDs, such as SYNGAP1.

> The phrase, \"critical period that is essential for the assembly and excitatory balance of developing forebrain circuits\" is obscure. I believe the authors mean -- the \" critical period during which a normal ratio of excitatory and inhibitory synapses are formed in particular brain regions. Without this normal ratio, the circuits can become overly excitable, leading to pathological function.\"

Thank you for pointing this out. We have changed the statement to read, "Sygnap1 heterozygosity disrupts a developmental critical period, which a normal ratio of excitatory and inhibitory synapses are formed in particular brain regions. Without this normal ratio, circuits can become overly excitable, which may contribute to pathological brain function (Clement et al., 2012; Ozkan et al., 2014)."

> At the beginning of the Discussion, the authors state, \"The principle finding of this study is that genetic reversal of Syngap1 pathogenicity in adult mice improves deficits in memory and excitability.\" This is another overgeneralization that is potentially confusing. The authors should state, \"The principal finding of this study is that genetic reversal of Syngap1 pathogenicity in adult mice improves deficits in long-term contextual memory and in seizure thresholds.\" In the next sentence, the authors should change the ending; \"... that mediate working memory.\" The paradox that the authors refer to arises solely from their own overgeneralization. The significance of the authors work would be more broadly accepted if they refrained from over-generalization in the first place.

We appreciate the advice from the reviewer, and we will be mindful of overgeneralizations in the future. We have rewritten the manuscript based on the substantial new data included in the study. In the new version of the manuscript, this statement has been changed to, "The principal finding in this study is that genetic reversal of Syngap1 pathogenicity in adult mice reverses deficits in remote memory, lowers seizure threshold, re-balances neural excitability, and improves hippocampal/cortical function. On the surface, these exciting results are somewhat paradoxical given that we have previously found that Syngap1 pathogenicity causes hardwired impairments in the development of forebrain circuits that mediate a subset of previously tested cognitive functions (30, 31, 47)."

Reviewer \#2:

> \[...\] The findings are interesting, but I am not sure whether they rise to the level of importance and novelty to warrant being published as a short report in eLife. As noted by the authors, similar findings in other mouse models of intellectual disability/autism spectrum disorder have demonstrated and in this manuscript there are no experiments designed to get at the mechanism or brain region where re-expression of Syngap1 is exerting this effect in adulthood.

Over the past year, we have performed substantial new experiments that: 1) get at the mechanism and brain regions that SynGAP re-expression may be exerting its influence, and 2) provide translational relevance to the mouse reversal studies. We believe that these new experiments increase the novelty and the general interest of our study.

Behavioral improvements reflecting improved cognitive function and reduced seizure susceptibility in the mouse model are now strengthened by data demonstrating a corresponding improvement in neurophysiological signals that predict seizure susceptibility and learning ability. These new studies demonstrate that protein replacement reversed both in vivo neurophysiological and behavioral phenotypes related to memory and seizure, two of the most clinically-relevant phenotypes associated with severe NDDs. Phenotypic reversal of cognitive deficits in this study was accompanied by chronic in vivo neurophysiological analysis in mice before and after gene restoration. This prospective design, which followed individual mice over two months, allowed us to measure how hippocampal and cortical function changed in individual animals after protein restoration in adulthood. In these new studies, we observed an increase in hippocampal theta power (a biomarker for memory formation) and an elimination of generalized paroxysmal spiking across the forebrain (a biomarker for seizure susceptibility) in mutant mice that underwent gene restoration. These clear improvements in hippocampal and cortical function provide mechanistic insight into how behavioral measures of seizure and memory improved after protein re-expression in adult animals. The combined improvement in both in vivo neurophysiology and behavior in response to adult gene repair provides very strong evidence that increasing the levels of pathologically low protein caused by severe genetic variants can broadly improve the function of the hippocampus and cortex even in mature animals.

We also now provide data from human SYNGAP1 patients that provide translational context to the electrophysiological studies in mice that are described above. We collected data from human patients that harbor similar genetic pathogenicity as the mouse models (i.e. haploinsufficiency of SYNGAP1/Syngap1). We found that both mouse models and human patients exhibited analogous pathological EEG waveforms, which was the tendency of interictal activity to increase during periods of sleep. In mice, the pathological waveforms biased toward sleep were abolished after adult-initiated protein restoration. Therefore, these pathological EEG waveforms are a promising candidate biomarker for generalized cortical dysfunction in this genetically-defined NDD. We have confidence in the validity of these signals as a candidate biomarker because the signals worsened during sleep in both species. Sleep-driven worsening of pathological EEG signals is associated with declining cognitive function in NDD patients. Therefore, abolishment of these signals in mice, combined with improved behavioral measures of long-term memory, suggest that EEG signals can be a proxy measure for generalized improvements in cognitive function in single-gene causes of NDDs. Past clinical trials for NDD treatments searching for improved cognitive function in patients have relied on subjective endpoints, such as parent-reported surveys. These endpoints suffer from a very high placebo effect, which can run up to 30%. EEG studies are easily performed in the clinic, even in children with severe NDDs, and signals collected from EEG are highly quantifiable. The objective nature of EEG signals suggest that they may be less prone to measurement bias leading to a lower placebo effect, and therefore may be more useful in clinical trials that test the efficacy of emerging therapies for genetically-defined NDDs.

> In addition, there is an interesting finding that is not explained: there is no remote memory phenotypes if the Syngap1 heterozygous mutant mice are tested one day after training, suggesting the retrieval of the memory prevents the remote memory impairment. How is does this observation impact the interpretation of the remote memory phenotype?

We reasoned that if retrieval at 1-day after training can prevent 30-day retrieval deficits, then networks that either consolidate and/or retrieved remote memory must be structurally intact in adult Syngap1 mice. We therefore hypothesized that these structurally-intact memory-linked circuits likely suffer from functional deficits caused by the persistent reduction of SynGAP protein expressed in the forebrain. It follows that restoring SynGAP protein in these circuits, even in adulthood, would improve memory performance in these mice. Our behavioral data supports this hypothesis. Importantly, our new in vivo ePhys data also supports this conclusion because we see clear evidence of improved hippocampal and cortical function in Syngap1 mutants after protein re-expression in adulthood. Moreover, we have shown in a past study, that adult restoration of SynGAP protein in Syngap1 Hets also rescues LTP in the CA1. Together, these data support the hypothesis that the Syngap1 gene retains functions in the adult brain to control the function and plasticity of forebrain circuits that promote memory and balance network excitability.

> In closing, although the findings are interesting and potentially important for understanding pathologies in adult Syngap1 mutant mice, I am not sure that they warrant publication in eLife.

We hope that the addition of human EEG data and the in vivo ePhys studies in Syngap1 rescue mice raise the enthusiasm of the reviewer.

Reviewer \#3:

> The manuscript by Thomas Creson et al. reported that re-expression in adults can reverse some behavioral and seizure abnormalities even though SynGAP loss disrupts neurodevelopment. Specifically, the authors showed evidence that 1) re-expression of SynGAP in adults reverses remote memory deficit in a SynGap1 Het mice with 50% SynGAP loss; 2) re-expression of SynGAP in adults also alleviates seizures in SynGap1 Het mice. These findings are interesting and worth publishing but they do not reach the level of significance expected for eLife. The seizures and remote memory phenotypes are very interesting, but they remain mostly unexplored in this manuscript. The finding that it is possible to reverse in adults certain behavioral and physiological phenotypes in neurodevelopmental mouse mutants is interesting and clinically relevant, but it is not novel, since it has been demonstrated repeatedly in multiple neurodevelopmental conditions.

We thank the reviewer for the insightful comments. The major concern, that the reversal of behaviors in adulthood in Syngap1 mice was largely unexplored in the original manuscript, has been dealt with in the revised manuscript. We now include two new and substantial experiments in the revised study to further explore the reversal phenotypes in this mouse model. We believe that these new experiments increase the novelty and the general interest of our study.

Behavioral improvements reflecting improved cognitive function and reduced seizure susceptibility in the mouse model are now strengthened by data demonstrating a corresponding improvement in neurophysiological signals that predict seizure susceptibility and learning ability. These new studies demonstrate that protein replacement reversed both [in vivo neurophysiological]{.ul} and [behavioral]{.ul} phenotypes related to memory and seizure, two of the most clinically-relevant phenotypes associated with severe NDDs. Phenotypic reversal of cognitive deficits in this study was accompanied by chronic in vivo neurophysiological analysis in mice before and after gene restoration. This prospective design, which followed individual mice over two months, allowed us to measure how hippocampal and cortical function changed in individual animals after protein restoration in adulthood. In these new studies, we observed an increase in hippocampal theta power (a biomarker for memory formation) and an elimination of generalized paroxysmal spiking across the forebrain (a biomarker for seizure susceptibility) in mutant mice that underwent gene restoration. These clear improvements in hippocampal and cortical function provide mechanistic insight into how behavioral measures of seizure and memory improved after protein re-expression in adult animals. The combined improvement in both in vivo neurophysiology and behavior in response to adult gene repair provides very strong evidence that increasing the levels of pathologically low protein caused by severe genetic variants can broadly improve the function of the hippocampus and cortex even in mature animals.

We also now provide data from human SYNGAP1 patients that provide translational context to the electrophysiological studies in mice that are described above. We collected data from human patients that harbor similar genetic pathogenicity as the mouse models (i.e. haploinsufficiency of SYNGAP1/Syngap1). We found that both mouse models and human patients exhibited analogous pathological EEG waveforms, which was the tendency of interictal activity to increase during periods of sleep. In mice, the pathological waveforms biased toward sleep were abolished after adult-initiated protein restoration. Therefore, these pathological EEG waveforms are a promising candidate biomarker for generalized cortical dysfunction in this genetically-defined NDD. We have confidence in the validity of these signals as a candidate biomarker because the signals worsened during sleep in both species. Sleep-driven worsening of pathological EEG signals is associated with declining cognitive function in NDD patients. Therefore, abolishment of these signals in mice, combined with improved behavioral measures of long-term memory, suggest that EEG signals can be a proxy measure for generalized improvements in cognitive function in single-gene causes of NDDs. Past clinical trials for NDD treatments searching for improved cognitive function in patients have relied on subjective endpoints, such as parent-reported surveys. These endpoints suffer from a very high placebo effect, which can run up to 30%. EEG studies are easily performed in the clinic, even in children with severe NDDs, and signals collected from EEG are highly quantifiable. The objective nature of EEG signals suggest that they may be less prone to measurement bias leading to a lower placebo effect, and therefore may be more useful in clinical trials that test the efficacy of emerging therapies for genetically-defined NDDs.

[^1]: These authors contributed equally to this work.
